

PRESS RELEASE

Cell4Cure has forged a strategic partnership with Bartlett Hill Partners to lead the North American Business Development activities for its Immune Tolerance Platform

Solna, Sweden, 4 March 2025, Cell4Cure AB – a Swedish, privately held biotech company, pioneering the development of immune tolerance therapies – today announced its strategic partnership with Bartlett Hill Partners LLC, a leading advanced therapies consulting group to lead its Business Development initiatives in North America.

Cell4Cure's proprietary, antigen-specific dendritic cell tolerance platform has been developed to negate the known problematic effect of Anti-Drug Antibodies on the tolerance and efficacy of biologic therapies. Through Bartlett Hill Partners, Cell4Cure will be introducing the antigen-specific dendritic cell tolerance platform to international pharma companies residing in North America and having marketed biologics treating patients with e.g. cancer, anti-inflammation, hemophilia. The platform could also be used for patients with autoimmune diseases or transplanted patients at risk of rejection.

Bartlett Hill Partners LLC was founded by John Manzello a globally recognized advanced therapy executive. Mr. Manzello will bring decades of advanced therapy experience to advise and handle Cell4Cure Business Development activities in North America and will lead the strategic advancement of the company's partnering activities there.

Christina Herder, CEO "We are excited to partner with Bartlett Hill Partners in order to strengthen our outreach in North America. The expertise and network they bring on will be instrumental in introducing our innovative platform to partners".

"Cell4Cure's antigen-specific dendritic cell tolerance platform is a genius approach for solving the acknowledged industry problem of Anti-Drug Antibodies (ADAs). Its broad applications could avail an entirely new dimension of tolerance for already proven biologic therapies." said John Manzello, Founder of Bartlett Hill Partners LLC

About Cell4Cure

Cell4Cure AB, a Swedish, privately held biotech company, founded in 2023, is pioneering immune tolerance therapies aimed at addressing significant clinical challenges such as anti-drug antibodies (ADAs), autoimmune diseases, and transplant rejections. The company's proprietary platform leverages ex vivo-generated dendritic cells (DCs) engineered to induce antigen-specific tolerance.

These tolerogenic DCs offer a targeted approach to mitigating unwanted immune responses while preserving essential immune functions.

Based on \$30 million in R&D investments, the technology platform has reached key development milestones, i.e. EMA approval for clinical trials, and the establishment of robust GMP manufacturing processes.

For more information, please contact;

Christina Herder, CEO

Telephone: +46 703747156

